Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB4 Monoclonal Antibody Relates to Apoptotic Cell Clearance
Fares Al-Ejeh, Alexander H Staudacher, Douglas R Smyth, Jocelyn M Darby, Delphine Denoyer, Chris Tsopelas, Rodney J Hicks, Michael P Brown
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2014
Awarded by NHMRC
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported in part by NHMRC project grant ID511303 and Oncaidia Ltd. Fares Al-Ejeh and Jocelyn M. Darby were employees of Oncaidia Ltd. Fares Al-Ejeh, Jocelyn M. Darby, and Michael P. Brown are coinventors on APOMAB patents owned by Medvet Pty Ltd. All authors had control of the data presented in this manuscript. No other potential conflict of interest relevant to this article was reported.